← All trials
NCT05119790
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 27, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Nov 30, 2021
- First posted
- Nov 15, 2021
- Last posted
- Nov 15, 2021
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BiogenLead sponsor
- Denali Therapeutics Inc.Study director
- Denali Therapeutics Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.